Study S003325

A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of RAY1225 Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

ClinicalTrials.gov record

Registration

Registration: NCT07139535
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 350
Start: 2025-08-31
Primary completion: 2026-12-01
Lead sponsor: Guangdong Raynovent Biotech Co., Ltd
Conditions: T2DM
Interventions: DRUG:RAY1225; DRUG:placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Baseline,36 Week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.